BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 24/04/2018

FDA Announces Draft Guidance for Nonclinical Development of Pharmaceuticals for Severely Debilitating or Life-Threatening Hematologic Disorders

The FDA is releasing a draft guidance to help pharmaceutical companies design nonclinical studies for treatments of severely debilitating or life-threatening hematologic disorders, aiming to bring new therapies to patients sooner.

Source: Federal Register — Food and Drug AdministrationOpen original release →